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Abstract
Background: Lowserum vitamin D levels are associated with susceptibility to, and severity of, multiple
sclerosis. High dose vitamin D has been proposed as a potential immunomodulator in multiple sclerosis.
Objectives: We performed a single centre, investigator-led, exploratory, double-blind, randomised,
placebo controlled, trial of vitamin D3 in clinically isolated syndrome and healthy control participants
to assess its immunological effects. Secondary end-points included clinical and magnetic resonance
imaging outcomes and safety.
Methods: Clinically isolated syndrome patients and healthy control participants were randomised to:
placebo, 5000 IU or 10,000 IU vitamin D3/day (Vigantol oil). Study duration was 24 weeks.
Results: The trial did not meet its primary end point, with no difference in the frequency of pro-
inflammatory CD4þ T cells (interleukin (IL)-17þ/interferon (IFN)-gþ) seen. A higher level of disease
freedom (67% versus 50%) was seen in those with serum 1,25 (OH) vitamin D levels>100 nmol/l but
this did not reach significance. High dose vitamin D3 was well tolerated with no safety signal.
Conclusions: High dose vitamin D3 over 24 weeks was well tolerated but without immunological, mag-
netic resonance imaging or clinical evidence of benefit. The hypothesised therapeutic effects in clinically
isolated syndrome or multiple sclerosis patients may require longer periods of administration or may only
be seen in patients treated with vitamin D3 as an adjunct to established disease modifying therapies.
Keywords: Multiple sclerosis, clinically isolated syndrome, vitamin D, randomised controlled trial,
immunology, cholecalciferol
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Introduction
Multiple sclerosis (MS) is a relapsing inflammatory dis-
order affecting the central nervous system causing
demyelination, axonal and neuronal injury resulting in
cerebral and spinal atrophy. Its pathogenesis is not fully
understood but involves a complex interplay between
genetic and environmental factors.1 There is a well
recognised geographical distribution of MS with
increased incidence and prevalence associated with lati-
tude from the equator.2 The association of both MS sus-
ceptibility and disease activity with low serum vitamin
D levels has emerged from a number of studies showing
increased prevalence with lower levels of ultraviolet
(UV) radiation3,4, a higher risk of MS in offspring of
women who are deficient in vitamin D5,6 which is fur-
ther supported by month of birth studies;7 also, higher
serum levels of vitamin D are associated with lower risk
of relapse8,9 and the number of new lesions on magnetic
resonance imaging (MRI) scanning.10
Vitamin D has been shown to modulate both the innate
and adaptive immune systems.11 The active metabolite,
1,25 (OH) vitamin D (25(OH)D), mediates its effects
through the intracellular vitamin D receptor (VDR),12
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which is present in monocytes, dendritic cells, B-cells
and CD4þ T cells.11,13 Activation of VDR alters tran-
scription, proliferation and differentiation of immune
cells12 and both indirectly modulates immune response
by reducing the activation of pro-inflammatory T cells
by antigen presenting cells14 and directly inhibiting
T cell and B cell proliferation.11,15 This results in
a Th2 cell driven anti-inflammatory state.13,15,16 The
diverse effects seen within the immune system in
response to vitamin D supplementation may explain
the conflicting results from the small number of
human studies carried out to date.1723
Clinically isolated syndrome (CIS) refers to patients
presenting with a first-ever symptom consistent with
demyelination and without evidence of dissemination
in time.24 CIS patients have a well-established natural
history, with an increased risk of MS associated with
the number of asymptomatic MRI T2 lesions at pres-
entation.25 In many countries, including Ireland, a
conservative approach of ‘watchful waiting’, rather
than the immediate introduction of disease-modifying
therapy, is taken. Vitamin D deficiency is common in
Ireland,26 as in many northern European countries and
may contribute to both disease susceptibility and dis-
ease severity. We hypothesised that treatment of CIS
patients with vitamin D3 supplementation might
reduce the risk of progression to either clinically- or
MRI-confirmed MS. Therefore we carried out a ran-
domised, double-blind, placebo-controlled trial of
vitamin D3 supplementation in CIS patients to
assess the immunological and therapeutic effects, if
any, of vitamin D3 supplementation in these patients.
Healthy control participants were also prospectively
recruited to investigate if the immunological
responses to vitamin D3 supplementation differed
between control participants and those with CIS. We
also wanted to determine whether high dose vitamin
D3 is a safe and effective therapy for patients with
CIS.
Participants and methods
Study participants
Inclusion criteria.
1. CIS patients aged between 1855 years with
symptom onset within three months of screen-
ing, having two or more asymptomatic T2
lesions on brain MRI consistent with demyelin-
ation, not treated with steroids within 30 days of
screening and not on any other disease-modifying
therapy.
2. Healthy control participants (HCPs) were aged
between 2040 years with a female: male ratio
of 2:1, broadly in line with the gender ratio
of CIS.
Exclusion criteria.
1. Exclusion criteria in both CIS patients and HCPs
were: no history or evidence of hypercalcaemia,
renal impairment, vitamin D intolerance, para-
thyroid dysfunction, sarcoidosis, pregnancy or
refusal to use contraception, prior or current
treatment with thiazide diuretics or vitamin D
supplementation of greater than 1000 IU/day.
2. Exclusion criteria in patients with CIS were: (a)
patients whose symptoms might be explained by
a diagnosis other than MS; (b) patients with
occurrence of an exacerbation less than six
weeks prior to entry to the study; (c) previous
treatment with any immunomodulating therapy
in the last three months, steroids in the last four
weeks or any previous treatment with mitoxan-
trone or other immunosuppressant.
Trial design
This was a single-centre, investigator-led, explora-
tory, double-blind, dose-ranging, randomised, pla-
cebo-controlled trial. A full detailed trial protocol
has been previously published.27 Detailed procedures
carried out at each study visit are available in
the Supplementary Material, Methods section.
Participants were enrolled from November 2012
and last study visit was June 2015. Both HCPs and
CIS patients were recruited over the same time
period and studied in parallel. Both the HCPs and
CIS patients were randomised to one of three inter-
ventions: placebo oil, 5000 IU and 10,000 IU vitamin
D3 per day. The vitamin D3 was in the form of
Vigantol Oil, supplied by Merck KgaA (Darmstadt,
Germany). Both placebo and the active product were
identical in appearance.
Endpoints
The primary endpoint was the effect of oral vitamin
D3 at 5000 IU and 10,000 IU per day compared to
placebo on the frequency of CD4þ T cell subsets
(interleukin (IL)-17þCD4þ T cells and interferon
(IFN)-gþCD4þ T cells) and cytokine (IL-17, IL-10
and IFN-g) responses in peripheral blood mono-
nuclear cells (PBMCs) in patients with CIS and
HCPs at 16 and 24 weeks compared to baseline.
Secondary endpoints included determining if, in CIS
patients, there was a difference in the response to
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5000 IU and 10,000 IU vitamin D3, compared to pla-
cebo in:
1. Radiological activity as measured by the number
of new or enlarging T2 lesions and gadolinium-
enhancing lesions on brain MRI at 24 weeks
compared to baseline.
2. Clinical activity as measured by the annualised
relapse rate (ARR), percentage of patients
relapse-free and time to first relapse.
3. Disease freedom as measured by the percentage
of patients with no evidence of either radio-
logical or clinical activity.
We also wished to determine the dose response and
safety and tolerability of high dose vitamin D3 sup-
plementation in both CIS patients and HCPs.
Study procedures
Study visits were performed at baseline and then
at four-weekly intervals over a 24-week period.
A follow-up visit was arranged at week 2830.
At each visit, changes in medical and neurological
history or medications were recorded. All patients
had a full physical examination and CIS participants
has their Expanded Disability Status Scale (EDSS)
score recorded and were assessed for any evidence of
a relapse. Treatment adherence, as measured by the
volume of study drug returned at each visit, and any
adverse events were also noted.
Vitamin D and parathyroid hormone
Plasma parathyroid hormone (PTH) levels were mea-
sured at baseline, week 4, 8, 16, 24 and 2830 using
the Roche intact PTH assay on the Cobas E411
Electrochemiluminescent Immunoassay Analyser
(Roche Diagnostics GmbH, Mannheim, Germany).
Serum 25(OH)D levels were measured by liquid
chromatography mass spectrometry (LC-MS/MS)
using a Waters Acquity ultra performance liquid chro-
matography (UPLC) coupled to a triple quadrupole
mass (TQD) (Waters Corp., Milford, USA) with a
semi-automated solid phase extraction (SPE) prepar-
ation of patient serum samples (Tecan Freedom Evo
100, Switzerland). A more detailed description is avail-
able in the Supplementary Material, Methods section.
Biochemistry, including urea and electrolytes, serum
creatinine, liver function and serum calcium levels
adjusted for albumin level, was measured at each
study visit.
Immunological outcome measures
PBMCs were isolated and cryopreserved, and
immunological analyses were performed upon com-
pletion of the study. PBMCs from all time-points were
thawed in batches, labelled with cell tracker dye
CellTrace Violet (CTV) (Invivogen), and cultured at
2 106 cells/ml in a 48-well plate (0.5 106 cells in
total) in complete Roswell Park memorial institute
(RPMI) medium and were left unstimulated or stimu-
lated with the following: 1mg/ml anti-CD3
(eBioscience), 0.5 106 irradiated allogeneic
PBMCs, 1 mg/ml each of purified protein derivative
(PPD; Serum Staten Institute) and tetanus toxoid
(TT) as recall antigens, and 0.625mg/ml/0.375 nM
each of myelin oligodendrocyte protein (MOG) and
myelin basic protein (MBP) PepTivator overlapping
peptides (Miltenyi Biotech). In parallel with each
batch of samples the same standardised PBMC
sample was included in order to monitor reproducibil-
ity between batches. After three days for anti-CD3, or
seven days for antigen-specific stimuli, cell culture
supernatants were removed and the concentrations of
IFN-g, IL-17 and IL-10 were analysed by enzyme-
linked immunosorbent assay (ELISA) (eBioscience).
In addition, the cells were restimulated with 50 ng/ml
phorbol myristate acetate (PMA), 500 ng/ml ionomy-
cin and 5mg/ml of Brefeldin A for five hours (all
Sigma), followed by staining for cell-surface CD3
and CD8 and intracellular IL-17 and IFN-g
(eBioscience). Cells were analysed by flow cytometry
using a BD LSRFortessa Cell Analyser (BD
Biosciences) and FlowJo software. T cell proliferation
was analysed by CTV dilution.
MRI acquisition
Brain MRI was acquired at baseline and 24 weeks
with contiguous axial 3 mm thick slices. Sequences
included: axial and coronal T1-weighted spin echo
(pre and post gadolinium), axial and sagittal PD/T2-
weighted and axial fast fluid-attenuated inversion
recovery (FLAIR). Baseline and 24-week scans
were reviewed by two radiologists who were blinded
to treatment group. MRI assessment included: (a)
number of gadolinium-enhancing lesions; (b) number
of new and enlarging T2 lesions; (c) total number
of new lesions¼ number of gadolinium-enhancing
lesions plus number of new and enlarging T2 lesions.
Statistical methods
Power calculations were based on a pilot study28
using a of 5% and b of 80%. A detailed description
is available in the Supplementary Material, Methods
section. All serum 25(OH)D levels were adjusted for
season29 and these values were used in all further
analysis. All data was inspected for normality
using histograms, skewness and kurtosis and normal-
ity tests (Kolmogorov-Smirnov and Shapiro-Wilk).
Values displayed include mean and standard devi-
ation (SD) or median and interquartile range where
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appropriate. Within group differences between base-
line and follow-up were assessed using the Wilcoxon
Rank test as outlined in the protocol. Log10 ratio of
week 16/baseline and week 24/baseline was calcu-
lated and adjusted for baseline measurements
(including vitamin D level) and between group dif-
ferences were compared using the t-test or Mann
Whitney U test where indicated. All analysis was
carried out in SPSS version 20.
Ethical approval
Ethical approval was granted by St Vincent’s
University Hospital Ethics and Medical Research
Committee and the study was approved by the Health
Products Regulatory Authority (HPRA). The trial was
registered with ClinicalTrials.gov (NCT01728922) and
the European Union Clinical Trials Register (EudraCT:
2012-000635-68).
Results
Study participants
Recruitment to the study is outlined in Figure 1.
Baseline characteristics of subjects in each treatment
arm are outlined in Table 1. All participants were
Caucasian. No significant differences were seen
between each of the three treatment arms in either
CIS patients or HCPs. Mean baseline EDSS was 0.9
(SD: 1), 0.9 (SD: 1.2) and 0.4 (SD: 0.5) in each of the
10,000 IU, 5000 IU and placebo groups respectively.
No patients were on disease modifying treatment as
per protocol.
Serum 25(OH)D, PTH and calcium levels
There was no difference in mean baseline serum
25(OH)D levels between CIS patients and HCP
(53 vs 52 nmol/l, p¼ 0.8). For the CIS group, in
the placebo, 5000 IU and 10,000 IU treatment
arms, mean changes in serum 25(OH)D levels
from baseline to week 16 were 7 nmol/l (SD: 26),
81 nmol/l (SD: 63) and 121 nmol/l (SD: 35); from
baseline to week 24, mean changes were 18 nmol/l
(SD: 34), 76 nmol/l (SD: 57) and 115 nmol/l (SD:
51) respectively. For the HCP group, in the pla-
cebo, 5000 IU and 10,000 IU treatment arms,
mean changes in serum 25(OH)D levels from base-
line to week 16 were 4 nmol/(SD: 12), 83 nmol/l
(SD: 27) and 152 nmol/l (SD: 71) and from
Figure 1. Schematic diagram outlining recruitment to the study, randomization and final analysis.
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baseline to week 24 were 2 nmol/l (SD: 14),
92 nmol/l (SD: 35) and 136 nmol/l (SD: 71)
respectively (Figure 2).
These changes were significant in both the 10,000 IU
and 5000 IU treatment arms when compared to pla-
cebo in both CIS patients and HCPs (p< 0.01).
Adjusting for baseline serum 25(OH)D levels, no
significant differences in serum 25(OH)D levels
achieved were seen between CIS patients and
HCPs in any treatment arm. No cases of hypercal-
caemia (reference range: 2.22.6 mmol/l) were
recorded in any participant. Mean plasma PTH
levels were lower in both treatment arms compared
to placebo at all time-points in both CIS patients
and HCPs.
Immunological responses to supplementation
The primary outcome of the study was the change in
T cell subsets (IFN-gþCD4þ/IL-17þCD4þ T cells)
in response to supplementation. No significant
reduction in either IFN-gþCD4þ/IL-17þCD4þ
T cells was seen in any treatment arm at any time-
point regardless of method of stimulation (polyclonal
or antigen specific with MOG/MBP peptides, recall
antigens (PPD/TT) or irradiated allogeneic PBMCs).
Results of polyclonal stimulation in both CIS
patients and HCPs are presented in Table 2 and anti-
gen-specific stimulation in CIS patients in Table 3.
Similarly no significant differences were observed in
concentrations as measured by ELISA of IL-10,
IL-17 and IFN-g produced followed stimulation of
PBMCs in any treatment arm (Supplementary
Figure 2. Graph showing median (boxes: 2575% interquartile range and error bars: minimummaximum) seasonally adjusted
serum 1,25 (OH) vitamin D (25(OH)D) levels (nmol/l) achieved in each of the treatment arms at baseline, week 16 and week 24.
CIS: clinically isolated syndrome; HCP: healthy control participant.
Table 1. Baseline characteristics of both clinically isolated syndrome (CIS) patients and healthy control participants (HCPs).
Clinically isolated syndrome
(n¼ 29)
Healthy control participants
(n¼ 38)
10,000 IU
(n¼ 12)
5000 IU
(n¼ 10)
Placebo
(n¼ 7)
10,000 IU
(n¼ 13)
5000 IU
(n¼ 13)
Placebo
(n¼ 12)
Female
n (%) 8 (67) 5 (50) 6 (86) 6 (46) 10 (77) 10 (83)
Age (years)
mean (SD) 37.2 (8.7) 32.7 (4.6) 34.3 (10.6) 30.5 (5.1) 30.3 (3.7) 29.1 (4.7)
BMI (kg/m2)
mean (SD) 30.6 (5.6) 26.3 (3.4) 26.7 (4.2) 25.4 (3.2) 23.5 (3.3) 27.6 (4.3)
Ever smoked
n (%) 7 (58) 5 (50) 3 (43) 2 (15) 3 (23) 4 (33)
BMI: body mass index; SD: standard deviation.
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Material, Table 1). Stratifying the groups based on
the increase in serum 25(OH)D level (<50 nmol/L/
50 nmol/L) seen at each time-point showed a trend
towards lower IFN-gþCD4þ proliferating T cells in
both CIS patients and HCPs with significance seen at
week 16 in CIS (p¼ 0.01) and week 16 (p¼ 0.03)
and week 24 (p¼ 0.02) in HCP (Figure 3). All values
were adjusted for baseline value but not for multiple
comparisons.
MRI results
Baseline and 24-week MRI scans were available in
26 CIS patients. An incorrect or incomplete protocol
was carried out in three patients. Baseline T2 lesions
and changes on follow-up MRI are outlined in
Table 4. No significant differences were seen
between the number of new lesions, or the proportion
of participants with new activity on follow-up MRI,
between groups, controlling for both baseline T2 and
gadolinium-enhancing lesions.
Clinical outcomes
One patient had a relapse during the course of the
study. Her symptoms began one day prior to her
week 24 visit. She had been allocated to the
5000 IU vitamin D3 treatment group equating to
mean ARR of 0.2 in this group. No patient fulfilled
standard EDSS criteria for evidence of disability pro-
gression. No significant difference in EDSS between
groups was seen at any time-point.
Combined clinical and radiological outcomes
Disease freedom at the end of the study as
measured by percentage of participants with no
evidence of MRI or clinical activity was 50%
(5/10), 33% (3/9) and 57% (4/7) in the 10,000 IU,
5000 IU vitamin D3 and placebo arms respectively.
Adjusting for baseline serum 25(OH)D level and,
comparing CIS patients with a serum 25(OH)D
level of <100 nmol/l at week 24 to those with
Table 2. Paired comparison between baseline and week 16 and baseline and week 24 of percentage interferon (IFN)-gþCD4þ
proliferating T cells and interleukin (IL)-17þCD4þ proliferating T cells amongst each treatment arm in both clinically isolated
syndrome (CIS) and healthy control participants (HCPs). Values are displayed as median and interquartile range.
CIS
Week 0 Week 16 p-Value Week 0 Week 24 p-Value
IFN-gþCD4þ
proliferating T cells
10,000 IU 7.3 (1.210.3) 7 (2.38.6) 0.646 7.3 (1.210.3) 5.1 (2.57.6) 0.169
5,000 IU 5.8 (3.36.8) 4.9 (3.610.2) 0.594 5.8 (3.36.8) 6.4 (4.78.6) 0.674
Placebo 4.7 (4.35.6) 7 (4.39) 0.043 4.7 (4.35.6) 6 (1.17.3) 0.6
IL-17þCD4þ
proliferating T cells
10,000 IU 0.8 (0.12) 1.3 (0.63.2) 0.015a 0.8 (0.12) 0.7 (0.32.9) 0.484
5000 IU 1.1 (0.62.9) 1.4 (0.82.9) 0.374 1.1 (0.62.9) 1.7 (0.52.4) 0.767
Placebo 0.3 (0.20.9) 0.6 (0.21.9) 0.046a 0.3 (0.20.9) 0.8 (013) 0.173
HCPs
Week 0 Week 16 p-Value Week 0 Week 24 p-Value
IFN-gþCD4þ
proliferating T cells
10,000 IU 9.3 (712.6) 11.3 (3.313.1) 0.94 9.3 (712.6) 8.9 (4.512.3) 0.29
5000 IU 8.5 (510.9) 6.5 (3.111.5) 0.59 8.5 (510.9) 8.2 (4.812.3) 0.93
Placebo 4.9 (2.57.5) 5.9 (1.412.6) 0.9 4.9 (2.57.5) 6.2 (3.812.6) 0.04b
IL-17þCD4þ
proliferating T cells
10,000 IU 0.6 (0.40.9) 0.5 (0.31.2) 0.37 0.6 (0.40.9) 0.7 (0.51.6) 0.46
5000 IU 1 (0.51.6) 0.6 (0.30.9) 0.18 1 (0.51.6) 0.5 (0.31.7) 0.86
Placebo 0.8 (0.31.5) 0.8 (0.31.9) 0.75 0.8 (0.31.5) 1.3 (0.42.8) 0.64
aA significant increase in Ll-17þCD4þ T cells seen at these time-points in the 10,000 IU and placebo groups; ba significant increase in
IFN-gþCD4þ T-cells was seen at this time-points in the placebo group.
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a level 100 nmol/l showed a disease freedom rate
of 50% (7/14) compared to 67% (8/12) (p¼ 0.4).
Safety and adverse events
There was one serious adverse event recorded
during the study; a patient required hospitalisation
for a lumbar discectomy. This event was reported
immediately to the study sponsor and the patient
withdrew from the study. However, the event
was felt to be unrelated to the study drug. At
the end of the study the patient was identified
as being in the placebo group. A full adverse
event listing is included as Supplementary
Material, Tables 2 and 3.
Table 3. Paired comparison between baseline and week 16 and baseline and week 24 of percentage interferon (IFN)-gþCD4þ
proliferating T cells and interleukin (IL)-17þCD4þ proliferating T cells from antigen-specific stimulated peripheral blood mono-
nuclear cells (PBMCs) from clinically isolated syndrome (CIS) patients. Values are displayed as median and interquartile range.
MOG/MBP stimulation
Week 0 Week 16 p-Value Week 0 Week 24 p-Value
IFN-gþCD4þ
proliferating T cells
10,000 IU 0.7 (0.11.1) 0.55 (0.21.9) p¼ 0.45 0.7 (0.11.1) 1.1 (0.51.9) p¼ 0.04a
5000 IU 0.95 (0.34.4) 1.13 (0.71.9) p¼ 0.39 0.95 (0.34.4) 1.3 (0.73.0) p¼ 0.29
Placebo 0.54 (0.21.4) 0.6 (0.21.1) p¼ 0.23 0.54 (0.21.4) 0.38 (0.20.9) p¼ 0.17
IL-17þCD4þ
proliferating T cells
10,000 IU 0.42 (0.11.0) 0.21 (0.10.7) p¼ 0.24 0.42 (0.11.0) 0.36 (0.10.9) p¼ 0.37
5000 IU 0.06 (0.030.2) 0.07 (0.030.3) p¼ 0.4 0.06 (0.030.2) 0.29 (0.050.4) p¼ 0.5
Placebo 0.1 (0.070.3) 0.37 (0.050.4) p¼ 0.23 0.1 (0.070.3) 0.14 (0.10.7) p¼ 0.9
PPD stimulation
Week 0 Week 16 p-Value Week 0 Week 24 p-Value
IFN-gþCD4þ
proliferating T cells
10,000 IU 0.45 (0.22.1) 0.87 (0.22.6) p¼ 0.44 0.45 (0.22.1) 1.2 (0.33.3) p¼ 0.04a
5000 IU 0.61 (0.41.7) 1.21 (0.62.1) p¼ 0.29 0.61 (0.41.7) 1.3 (0.62.6) p¼ 0.61
Placebo 0.69 (0.051.6) 1.19 (0.41.9) p¼ 0.04a 0.69 (0.051.6) 0.37 (0.12.9) p¼ 0.46
IL-17þCD4þ
proliferating T cells
10,000 IU 0.27 (0.73.0) 0.27 (0.11.6) p¼ 0.7 0.27 (0.73.0) 0.38 (0.12.0) p¼ 0.7
5000 IU 0.13 (0.010.4) 0.12 (0.040.3) p¼ 0.88 0.13 (0.010.4) 0.22 (0.040.4) p¼ 0.8
Placebo 0.49 (0.21.4) 0.56 (0.30.9) p¼ 0.47 0.49 (0.21.4) 0.29 (0.11.1) p¼ 0.23
Allogeneic stimulation
Week 0 Week 16 p-Value Week 0 Week 24 p-Value
IFN-gþCD4þ
proliferating T cells
10,000 IU 1.24 (0.72.7) 1.1 (0.93.1) p¼ 0.89 1.24 (0.72.7) 1.74 (0.62.9) p¼ 0.95
5000 IU 4.5 (1.3 (1.37.7) 1.5 (0.92.7) p¼ 0.02b 4.5 (1.37.7) 1.75 (0.82.8) p¼ 0.008b
Placebo 0.89 (0.31.3) 1.1 (0.61.7) p¼ 0.69 0.89 (0.31.3) 1.6 (0.11.7) p¼ 0.35
IL-17þCD4þ
proliferating T cells
10,000 IU 1.15 (0.31.8) 0.73 (0.21.6) p¼ 0.31 1.15 (0.31.8) 0.14 (0.11.4) p¼ 0.07
5000 IU 0.52 (0.21.2) 0.33 (0.20.5) p¼ 0.14 0.52 (0.21.2) 0.43 (0.11.8) p¼ 0.77
Placebo 0.2 (0.10.6) 0.51 (0.30.7) p¼ 0.27 0.2 (0.10.6) 0.56 (0.30.8) p¼ 0.35
aA significant increase in IFN-gþCD4þ proliferating T cells at that time point; ba significant reduction in IFN-gþCD4þ proliferating T cells at
that time point.
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Discussion
This trial showed that vitamin D3 supplementation at
doses of 5000 IU and 10,000 IU per day is both safe
and tolerable and results in significant increases in
serum 25(OH)D levels in both healthy controls and
CIS patients. It seems probable that serum 25(OH)D
levels of greater than 100 nmol/l are required to pro-
duce the immunological effects of vitamin D,
although no consensus level exists.29 A diminished
serologic response to vitamin D3 supplementation
has been described in MS patients compared to con-
trols raising the possibility of different vitamin D
pharmacokinetics in people with MS.30 In our study,
a higher mean change in serum 25(OH)D levels was
seen in the control group but this was not statistically
significant. Given the relatively small sample size it
was not possible to adjust for a number of confoun-
ders including age, sex and body mass index (s) across
each of the treatment arms.
Analysis of the primary outcome showed no differ-
ence in the frequency of pro-inflammatory CD4þ
T cells (IL-17þCD4þ/IFN-gþCD4þ) between base-
line and either time-point in any of the treatment
arms. No difference was seen between randomisation
groups or in response to varying methods of PBMC
stimulation (polyclonal or antigen-specific). A sig-
nificant reduction in proliferating IFN-gþCD4þ
T-cells was seen in both control participants (week
16 and 24) and CIS patients (week 16) when the
groups were stratified according to change in
serum 25(OH)D level but these results were not
Figure 3. Comparison between change in interferon (IFN)-gþCD4þ proliferating T cells, and interleukin (IL)-17þCD4þ pro-
liferating T cells between baseline and week 16 and baseline and week 24 between CIS and HCP. Values are expressed as a log10
ratio of week 16/baseline and week 24/baseline. The clinically isolated syndrome (CIS) and healthy control participant (HCP)
groups have been stratified into two groups based on a change in serum 1,25 (OH) vitamin D (25(OH)D) of <50 nmol/l and
50 nmol/l seen at each time-point.
Table 4. Baseline T2 lesions on magnetic resonance imaging (MRI) and change in follow-up scan at 24 weeks per randomised
group.
10,000 IU VD
(n¼ 10)
5000 IU VD
(n¼ 9)
Placebo
(n¼ 7)
Baseline T2 lesions
Mean (SD)
18 (17) 23 (11) 13 (10)
Baseline GD-enhancing lesions
Mean (SD)
0.3 (0.7) 0.3 (0.5) 0.1 (0.4)
New T2 lesions
Mean (SD)
0.4 (0.5) 1.4 (1.7) 0.6 (0.8)
New GD-enhancing lesions
Mean (SD)
0 0.1 (0.3) 0.1 (0.4)
Number of patients with new disease activity by MRI (%) 5 (50%) 5 (56%) 3 (43%)
GD: gadolinium; SD: standard deviation; VD: vitamin D.
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adjusted for multiple comparisons and need to be
interpreted with caution. Measurement of anti-
inflammatory (IL-10) and pro-inflammatory (IL-17/
IFN-g) cytokines from stimulated PBMCs by ELISA
also failed to show any significant changes in
response to supplementation or between randomisa-
tion groups.
The role of IL-17þCD4þ T cells in MS pathogenesis
has been shown in the experimental autoimmune
encephalitis (EAE) model, and is also supported by
high levels of IL-17 in MS plaques and cerebrospinal
fluid.31 In vitro studies have suggested that vitamin D
significantly inhibits IL-17 production and increases
IL-10 in relapsing remitting MS (RRMS) patients and
controls.11 However, the results of a small number of
published clinical trials exploring various immuno-
logical outcomes in response to vitamin D supplemen-
tation in MS have been conflicting and somewhat
disappointing in identifying the underlying molecular
immunological mechanism of vitamin D supplemen-
tation.1723 A recent study by Sotirchos et al. showed a
reduction in IL-17þCD4þT cells at week 24 in RRMS
patients receiving high dose (10,400 IU/day) vitamin
D3.
17 These effects were not observed in the low dose
group (800 IU/day) group and no significant change
was seen in IFN-gþCD4þ T cells in either group. A
Dutch sub-study of a larger clinical trial exploring high
dose (up to 14,000 IU/day) vitamin D3 supplementa-
tion, as an add-on therapy to interferonb-1 a in patients
with RRMS, showed no difference in either IL-
17þCD4þ or IFN-gþCD4þ T cells at 48 weeks
follow-up.22 The investigators found a reduction in
the proportion of anti-inflammatory IL-4þCD4þ T
cells in the placebo group and suggested that supple-
mentation may contribute to immune homeostasis early
in the disease course.
There were methodological differences in the pro-
cessing of PBMCs between these studies and our
own which may have contributed towards the differ-
ent percentages of IL-17þCD4þ and IFN-gþCD4þ
T cells seen. The experimental design of our study
was in part similar to that of Sotirchos et al. in that
intracellular cytokines were measured by restimula-
tion after an initial in vitro stimulation period using
cryopreserved PBMC. However, we cultured cells
for three rather than five days with anti-CD3, and
included additional antigen-specific stimuli. The
rationale for including antigen-specific stimuli was
that vitamin D3 is likely to exert at least some of its
anti-inflammatory effects on T cells via antigen-pre-
senting cells, and such effects may not be apparent
after polyclonal stimulation. The allogeneic stimula-
tion would be expected to stimulate naı¨ve allo-specific
T cells and would therefore reveal possible effects of
vitamin D3 on T cell differentiation, whereas recall
antigens PPD/TT or putative MS auto-antigens MOG/
MBP would restimulate antigen-specific memory T
cells. In contrast, Muris et al. measured intracellular
cytokine production directly ex vivo without cryo-
preservation or an in vitro stimulation period.22
Although our study was designed to examine the
effects of vitamin D3 supplementation on T cell
responses either directly or indirectly via the antigen
presenting cell, it is possible that vitamin D3 may
also exert other immunologic effects that were not
examined here. It has been suggested that vitamin D
may have immunomodulatory effects on B cells32,
regulatory T cells33 and dendritic cells.34
The discordance between published results to date
may suggest alternative hypotheses as to the observed
association between vitamin D deficiency and MS. It
has been argued that low serum 25(OH)D levels seen
early in the disease course are a result of the disease
itself and supplementation is unlikely to affect disease
activity.35 Alternative environmental factors need to
be considered. Ultraviolet exposure has been shown
to have immunomodulating effects on skin lympho-
cytes36 and thus, observed vitamin D deficiency may
only be a marker of lack of sunlight exposure.
Exploration of secondary endpoints showed no dif-
ference between treatment arms and placebo with
regard to either radiological or clinical activity.
A higher level of disease freedom (67% versus
50%) was seen in patients with serum 25(OH)D
levels >100 nmol/l but this was not significant. The
trial was not powered to meet this endpoint and the
trial duration was probably too short to detect a treat-
ment effect of vitamin D3 supplementation.
It is possible that high dose vitamin D3 therapy on its
own may not be sufficiently effective as an anti-
inflammatory or immunomodulatory therapy in MS
or CIS. There is convincing evidence, from a post-
hoc analysis, that higher serum 25(OH)D levels in
patients recruited into the BENEFIT and BEYOND
studies had additional therapeutic effects on disease
activity in patients on betaferon-1 b.37,38 Recent
results from the SOLAR study of high dose vitamin
D3 supplementation as an add-on therapy to inter-
feronb-1 a, showed a non-significant reduction in
the annualised relapse rate of 30% in the vitamin
D3 group at 48 weeks.
39 A significant reduction
in both unique new lesions and percentage change
in T2 lesion volume on MRI was also seen suggest-
ing a therapeutic benefit of supplementation.
That study was hampered by difficulty with
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recruitment leading to a reduced trial duration.
Longer follow-up and larger numbers are needed to
confirm these findings. A number of trials are
ongoing to address this issue.40,41
The strengths of this study are that it was a double-
blind randomised controlled trial and the first clinical
trial of vitamin D3 therapy in treatment-naı¨ve CIS
patients. The HCP group allowed us to establish if
immunological effects observed were unique to a
CIS population. There were limitations to our
study. Power calculations were based on a small
pilot study28 and may have resulted in the study
being underpowered. Difficulty with recruitment in
the CIS group also led to smaller numbers than ori-
ginally anticipated. The CIS group had a higher
mean age than controls, which is a potential con-
founder when comparing results of some of the sec-
ondary immunologic outcomes and vitamin D
pharmacokinetics. Our results were adjusted for
baseline values but not for multiple comparisons,
which may limit their interpretability.
Conclusion
In conclusion, this study demonstrates that vitamin
D3 supplementation at doses up to 10,000 IU daily is
safe and tolerable in both HPCs and CIS patients.
High dose vitamin D3 supplementation did not
reduce pro-inflammatory IL-17þCD4þ T cells;
there were possible minor effects on IFN-gþ CD4þ
T cells, but no changes were observed in concentra-
tions of IL-10, IL-17 or IFN-g produced by stimu-
lated PBMCs. The potential role of vitamin D3 as an
immunomodulator needs to be further clarified in
larger randomised controlled trials.
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